28 -1 (87) 2026 - Samadov F.F., Mahamadjonov I.A. - THE ROLE OF BIOMARKERS AND ELASTOGRAPHY IN THE ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HEPATITIS

THE ROLE OF BIOMARKERS AND ELASTOGRAPHY IN THE ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HEPATITIS

Samadov F.F. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Mahamadjonov I.A. - Tashkent Regional Infectious Diseases Hospital, Tashkent region, Chirchik city

Nurxonov F.T. - Republic Specialized Scientific and Practical Medical Center for Epidemiology, Microbiology, Infectious and Parasitic Diseases, Bukhara Branch

Abdurakhmonov D.A. - Republic Specialized Scientific and Practical Medical Center for Epidemiology, Microbiology, Infectious and Parasitic Diseases, Kashkadarya Branch

Resume

This review highlights modern non-invasive approaches for the assessment of liver fibrosis in chronic viral hepatitis, focusing on serum biomarkers and elastography techniques. Due to the invasiveness and limitations of liver biopsy, alternative diagnostic tools such as indirect and direct biomarkers, FibroScan, shear wave elastography, and magnetic resonance elastography have gained clinical importance. These methods allow early detection of fibrosis stages, evaluation of disease progression, and monitoring of antiviral therapy outcomes. A combined diagnostic strategy improves accuracy and supports evidence-based clinical decision-making in hepatology.

Keywords: liver fibrosis, chronic hepatitis, biomarkers, elastography, FibroScan, non-invasive assessment.

First page

149

Last page

154

For citation:Samadov F.F., Mahamadjonov I.A., Nurxonov F.T., Abdurakhmonov D.A. - THE ROLE OF BIOMARKERS AND ELASTOGRAPHY IN THE ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HEPATITIS//New Day in Medicine 1(87)2026 149-154 https://newdayworldmedicine.com/en/new_day_medicine/1-87-2026

List of References

1. World Health Organization. Global Hepatitis Report 2023. Geneva: WHO; 2023. (Scopus cited)
2. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis. Journal of Hepatology. 2021;75(3):659–689.
3. Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with chronic hepatitis C. Gastroenterology. 2019;156(5):1264–1281.
4. Tapper EB, Lok AS. Use of liver imaging and biopsy in clinical practice. New England Journal of Medicine. 2017;377:756–768.
5. Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology. 2009;49(3):1017–1044.
6. Bedossa P. Pathology of liver fibrosis. Biochimica et Biophysica Acta. 2013;1832(7):1030–1036.
7. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiological Reviews. 2008;88(1):125–172.
8. Bataller R, Brenner DA. Liver fibrosis. Journal of Clinical Investigation. 2005;115(2):209–218.
9. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–1325.
10. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–526.

    file

    download